29 – 30 September 2020, virtual event
The Financial Times US Pharma and Biotech Summit brings together industry leaders and experts to share insights and perspectives on the critical issues set to re-shape the sector in the wake of the COVID-19 pandemic.
As a lead sponsor, ICON is pleased to offer senior executives at clients and other third parties, a complimentary pass for this premier digital event supported by the world's best journalism. Passes / tickets are limited to maximum two per client - to be registered simply complete the short form and we will contact you.
Robert Bradway, Chairman and CEO, Amgen
Alexander Hardy, CEO, Genentech
Leonard Schleifer, Co-Founder, President and CEO, Regeneron
Stéphane Bancel, CEO, Moderna
Stephen M. Hahn, Commissioner, U.S. Food & Drug Administration (FDA)
Joanne Waldstreicher, Chief Medical Officer, Johnson & Johnson
Husseini Manji, Global Head, J&J Science for Minds, Johnson & Johnson
Bernard Hamelin, Global Head of Medical Evidence Generation, Sanofi
Jessica Mega, Chief Medical & Scientific Officer, Verily
Cristina Ortega Duran, Chief Digital Health Officer R&D, AstraZeneca
Kim Branson, Senior Vice President, Global Head of AI and Machine Learning, GSK
Rich Carter, VP, Chief Digital Officer, Eli Lilly & Company
Chief Commercial Officer, ICON plc
2:30pm - 2:55pm EST
Fireside chat: Interviewed by Sarah Neville, Global Pharmaceuticals Editor, Financial Times
Executive Vice President of Scientific Operations, ICON plc
12:40pm -1:25pm EST
Panel: Accelerating Drug Development to Save Time, Money and Lives
The coronavirus crisis has publicly exposed the difficulties of developing drugs quickly when needed. Now is the time to look at how product development processes can be made faster and more dynamic without losing trust. Technology surely has a big role to play but so do regulators, policymakers and patients.
Andy Garrett, Executive Vice President, Scientific Operations, ICON
Kim Branson, Global Head of AI and Machine Learning, GSK
Cristina Ortega Duran, Chief Digital Health Officer, R&D, AstraZeneca
Moderator: Sarah Neville, Global Pharmaceuticals Editor, Financial Times
VP, Drug Development Services and Global Head of Vaccine Center of Excellence, ICON plc
1:40pm -2:40pm EST
Roundtable: The Hunt for a Covid-19 Vaccine - Mapping the Critical Success Factors for Clinical Trial Success
Moderator: Cynthia Dukes
The hunt for a coronavirus vaccine is intensifying, and developers are facing an unprecedented level of scrutiny as they move their vaccine candidates into the crucial Phase 3 clinical trials – the longest, most expensive and high-stakes part of the process. Time is of the essence, leaving little margin for error, but developers must grapple with a range of hurdles and uncertainties before their much-anticipated products can make the leap from the lab to patients : they must design and conduct late-stage clinical trials in conditions of a pandemic, and in a way that allows them to demonstrate the full efficacy of their candidates, and they must meet the regulators’ evolving guidelines for the conduct of Covid-19 clinical trials and their needs for high-quality data. Success in these endeavours brings not only commercial opportunities, but the value that comes from enhanced reputation.